Durable response to crizotinib in a patient with lung adenocarcinoma harbouring low-level MET amplification but strong MET expression

被引：0
|
作者：
Riedel, R. [1 ]
Michels, S. [1 ]
Heydt, C. [2 ]
Nogova, L. [1 ]
Fischer, R. N. [1 ]
Abdulla, D. S. Y. [1 ]
Scheffler, M. [1 ]
Merkelbach-Bruse, S. [2 ]
Kobe, C. [3 ]
Schaefer, S. [2 ]
Buettner, R. [2 ]
Wolf, J. [1 ]
机构：
[1] Uniklin Koln, Klin Innere Med 1, Cologne, Germany
[2] Uniklin Koln, Inst Pathol, Cologne, Germany
[3] Uniklin Koln, Klin Nukl Med, Cologne, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P910
引用
收藏
页码：295 / 296
页数：2
相关论文
共 50 条
  • [31] Response to crizotinib and cabozantinib in stage IV lung adenocarcinoma patients with mutations that cause MET exon 14 skipping.
    Paik, Paul K.
    Drilon, Alexander E.
    Yu, Helena Alexandra
    Krug, Lee M.
    Rekhtman, Natasha
    Borsu, Laetitia
    Ginsberg, Michelle S.
    Berger, Michael F.
    Ladanyi, Marc
    Rudin, Charles M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] Durable complete response after afatinib and crizotinib in an advanced non-small cell lung cancer patient with EGFR L861Q mutation and acquired MET amplification: a case report
    Long, Yaling
    Zhang, Kai
    Li, Yanying
    Yu, Min
    Zhu, Jiao
    Huang, Meijuan
    ANNALS OF PALLIATIVE MEDICINE, 2020, 9 (05) : 3609 - 3613
  • [33] Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation
    Wiesweg, Marcel
    Herold, Thomas
    Metzenmacher, Martin
    Eberhardt, Wilfried E.
    Reis, Henning
    Darwiche, Kaid
    Aigner, Clemens
    Stuschke, Martin
    Herrmann, Ken
    Nensa, Felix
    Schildhaus, Hans-Ulrich
    Schuler, Martin
    LUNG CANCER, 2020, 139 : 165 - 168
  • [34] A Lung Adenocarcinoma with Concomitant EGFR And De Novo MET Amplification Response Well to Combination of TKI And Bevacizumab
    Chu, Q.
    Jiang, J.
    Huang, S.
    Zhang, P.
    Chen, Y.
    Zhang, T.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1075 - S1076
  • [35] A Lung Adenocarcinoma with Concomitant EGFR and de novo MET Amplification Response Well to Combination of TKI and Bevacizumab
    Chu, Q.
    Jiang, J.
    Huang, S.
    Zhang, P.
    Chen, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S980 - S981
  • [36] Dramatic Response to Crizotinib in a Patient With Lung Cancer Positive for an HLA-DRB1-MET Gene Fusion
    Davies, Kurtis D.
    Ng, Terry L.
    Estrada-Bernal, Adriana
    Le, Anh T.
    Ennever, Peter R.
    Camidge, D. Ross
    Doebele, Robert C.
    Aisner, Dara L.
    JCO PRECISION ONCOLOGY, 2017, 1 : 1 - 6
  • [37] A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib
    Mahjoubi, Linda
    Gazzah, Anas
    Besse, Benjamin
    Lacroix, Ludovic
    Soria, Jean-Charles
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (03) : 397 - 398
  • [38] A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib
    Linda Mahjoubi
    Anas Gazzah
    Benjamin Besse
    Ludovic Lacroix
    Jean-Charles Soria
    Investigational New Drugs, 2016, 34 : 397 - 398
  • [39] Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma
    Shea, Meghan
    Huberman, Mark S.
    Costa, Daniel B.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (07) : E81 - E82
  • [40] Patient with EGFR-mutant lung cancer harboring de novo MET amplification successfully treated with gefitinib combined with crizotinib
    Gu, Zhen-Bang
    Liao, Ling-Min
    Yao, Gong-Ji
    Fang, Ming
    Huang, Long
    CURRENT PROBLEMS IN CANCER, 2021, 45 (05)
12345